Wednesday, January 08, 2025 BRC5 Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non–small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). The Journal of Thoracic and Cardiovascular Surgery 167: 338-347.e1. 2024.https://www.sciencedirect.com/science/article/pii/S0022522323006128 In this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups. PAC3Zhao A, Tu D, He Y, Liu L, Wu B, Ren Y. Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy (ONLINE). Frontiers in Genetics 15: 1497254. 2024.https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2024.1497254 GEM-E has not shown a significant advantage over GEM in the treatment of pancreatic cancer. However, we discovered some patients who are sensitive to the GEM-E therapy based on the predictive biomarkers, which suggest that the predictive biomarkers provide ideas for personalized medicine in pancreatic cancer.
